Pediatric rhabdomyosarcoma of the head and neck

Current Treatment Options in Oncology

Volumn 7, Issue 1, 2006, Pages 13-22

  Gillespie, M Boyd ^a   Marshall, David T ^b   Day, Terry A ^b   Mitchell, Allen O ^b   White, David R ^b   Barredo, Julio C ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACTINOMYCIN; GROWTH HORMONE; IRINOTECAN; THYROID HORMONE; VINCRISTINE;

ABNORMAL BODY BUILD; CANCER CONTROL; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; CRANIOTOMY; ENDOSCOPIC SURGERY; FACE MALFORMATION; GROWTH RETARDATION; HEAD AND NECK CANCER; HEARING LOSS; HISTOPATHOLOGY; HUMAN; KYPHOSIS; LEARNING DISORDER; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALOCCLUSION; MORBIDITY; MULTIMODALITY CANCER THERAPY; PATIENT REFERRAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; RHABDOMYOSARCOMA; SALVAGE THERAPY; SCOLIOSIS; SECOND CANCER; SURGICAL TECHNIQUE; TREATMENT PLANNING; VISUAL DISORDER;

BIOPSY; CHILD; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; PATIENT CARE PLANNING; PROGNOSIS; RHABDOMYOSARCOMA; SALVAGE THERAPY; SURVIVAL;

EID: 31344460054     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0028-3     Document Type: Review

References (29)

1. Dagher R, Helman L: Rhabdomyosarcoma: an overview. Oncologist 1999, 4:34-44.
2. Walterhouse DO, Pappo AS, Baker KS, et al.: Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. A report from the Intergroup Rhabdomyosarcoma Study Group. Cancer 2001, 92:3135-3146.
3. Maurer HM, Beltangady M, Gehan EA, et al.: The Intergroup Rhabdomyosarcoma Study-I. Cancer 1988, 61:209-220.
4. Maurer HM, Gehan EA, Beltangady M, et al.: The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993, 71:1904-1922.
5. Crist W, Gehan EA, Ragab AH, et al.: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995, 13:610-630.
6. Crist W, Anderson JR, Meza JL, et al.: Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol 2001, 19:3091-3102.
7. Postec F, Bossard D, Distant F, Froelich P: Computer-assisted navigation system in pediatric intranasal surgery. Arch Otolaryngol Head Neck Surg 2002, 128:797-800.
8. Banhiran W, Casiano RR: Endoscopic sinus surgery for benign and malignant nasal and sinus neoplasms. Curr Opin Otolaryngol Head Neck Surg 2005, 13:50-54.
9. Yuen AP, Fan YW, Fung CF, Hung KN: Endoscopic-assisted craniofacial resection of olfactory neuroblastoma. Head Neck 2005, 27:488-493.
10. Daya H, Chan HSL, Sirkin W, Forte V: Pediatric rhabdomyosarcoma of the head and neck: Is there a place for surgical management? Arch Otolaryngol Head Neck Surg 2000, 126:468-472.
11. Godzinski J, Flamant F, Rey A, et al.: Value of postchemotherapy bioptical verification of complete clinical remission in previously incompletely resected (stage I and IIpT3) malignant mesenchymal tumors in children: International Society of Pediatric Oncology 1984 Malignant Mesenchymal Tumors Study. Med Pediatr Oncol 1994, 22:22-26.
12. Genden EM, Buchbinder D, Chaplin JM, et al.: Reconstruction of the pediatric maxilla and mandible. Arch Otolaryngol Head Neck Surg 2000, 126:293-300.
13. Lydaki E, Bolonaki I, Stiakaki E, Kambourakis A: Immediate free flap mandibular reconstruction in osteosarcoma of the mandible in childhood. Pediatr Hematol Oncol 2000, 17:335-340.
14. Stelnicki EJ, Boyd JB, Nott RL, et al.: Early treatment of severe mandibular hypoplasia with distraction mesenchymogenesis and bilateral free fibular flaps. J Craniofac Surg 2001, 12:337-348.
15. Houghton P, Cheshire P, Hallman J: Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-peperidinol-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993, 53:2823-2829.
16. Houghton PJ, Chehire PJ, Hallman JD, et al.: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of humor tumors. Cancer Chemother Pharmacol 1995, 36:393-403.
17. Furman WL, Stewart CF, Poquette CA, et al.: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999, 17:1815-1824.
18. Rodriguez-Galindo C, Radomski K, Stewart CF, et al.: Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 2000, 35:385-402.
19. Parliament MB, Scrimger RA, Anderson SG, et al.: Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity-modulated radiotherapy (IMRT) for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004, 58:663-673.
20. Garden AS, Morrison WH, Rosenthal DI, et al.: Target coverage for head and neck cancers treated with IMRT: review of clinical experiences. Semin Radiat Oncol 2004, 14:103-109.
21. Hong TS, Tome WA, Chappell RJ, et al.: The impact of daily setup variations on head-and-neck intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005, 61:779-788.
22. Michalski JM, Meza J, Breneman JC, et al.: Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys 2004, 59:1027-1038.
23. Parsons JT, Bova FJ, Fitzgerald CR, et al.: Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994, 30:765-773.
24. Monroe AT, Bhandare N, Morris CG, et al.: Preventing radiation retinopathy with hyperfractionation. Int J Radiat Oncol Biol Phys 2005, 61:856-864.
25. Bhandare N, Monroe AT, Morris CG, et al.: Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys 2005, 62:1070-1077.
26. Pappo AS, Meza JL, Donaldson SS, et al.: Treatment of localized nonorbital, nonparameningeal head and neck rhabdomyosarcoma: lessons learned from Intergroup Rhabdomyosarcoma studies III and IV. J Clin Oncol 2003, 21:638-645.
27. Donaldson SS, Meza J, Breneman JC, et al.: Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma - a report from the IRSG. Int J Radiat Oncol Biol Phys 2001, 51:718-728.
28. Oberlin O, Rey A, Anderson J, et al.: Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. J Clin Oncol 2001, 19:197-204.
29. Raney RB, Asmar L, Vassilopoulou-Sellin R, et al.: Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: a descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and -III. Med Pediatr Oncol 1999, 33:362-371.